Literature DB >> 12970409

Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs.

Yasuko Tsunetsugu-Yokota1, Yuko Morikawa, Maya Isogai, Ai Kawana-Tachikawa, Takashi Odawara, Tetsuya Nakamura, Fernanda Grassi, Brigitte Autran, Aikichi Iwamoto.   

Abstract

To evaluate the immunogenicity of human immunodeficiency virus (HIV) type 1 p55(gag) virus-like particles (VLPs) released by budding from yeast spheroplasts, we have analyzed the effects of yeast VLPs on monocyte-derived dendritic cells (DCs). Yeast VLPs were efficiently incorporated into DCs via both macropinocytosis and endocytosis mediated by mannose-recognizing receptors, but not the mannose receptor. The uptake of yeast VLPs induced DC maturation and enhanced cytokine production, notably, interleukin-12 p70. We showed that yeast membrane components may contribute to DC maturation partly through Toll-like receptor 2 signaling. Thus, Gag particles encapsulated by yeast membrane may have an advantage in stimulating Gag-specific immune responses. We found that yeast VLPs, but not the control yeast membrane fraction, were able to activate both CD4(+) and CD8(+) T cells of HIV-infected individuals. We tested the effect of cross-presentation of VLP by DCs in two subjects recruited into a long-term nonprogressor-slow progressor cohort. When yeast VLP-loaded DCs of these patients were cocultured with peripheral blood mononuclear cells for 7 days, approximately one-third of the Gag-specific CD8(+) T cells were activated and became perforin positive. However, some of the Gag-specific CD8(+) T cells appeared to be lost during in vitro culture, especially in a patient with a high virus load. Our results suggest that DCs loaded with yeast VLPs can activate Gag-specific memory CD8(+) T cells to become effector cells in chronically HIV-infected individuals, but there still remain unresponsive Gag-specific T-cell populations in these patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970409      PMCID: PMC228384          DOI: 10.1128/jvi.77.19.10250-10259.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles.

Authors:  R Wagner; L Deml; R Schirmbeck; M Niedrig; J Reimann; H Wolf
Journal:  Virology       Date:  1996-06-01       Impact factor: 3.616

2.  High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation.

Authors:  A C McNeil; W L Shupert; C A Iyasere; C W Hallahan; J A Mican; R T Davey; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells.

Authors:  F Re; J L Strominger
Journal:  J Biol Chem       Date:  2001-07-26       Impact factor: 5.157

4.  Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-like particles.

Authors:  G T Layton; S J Harris; A J Gearing; M Hill-Perkins; J S Cole; J C Griffiths; N R Burns; A J Kingsman; S E Adams
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

5.  The expression of hybrid HIV:Ty virus-like particles in yeast.

Authors:  S E Adams; K M Dawson; K Gull; S M Kingsman; A J Kingsman
Journal:  Nature       Date:  1987 Sep 3-9       Impact factor: 49.962

6.  Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells.

Authors:  Xiao-Qing Zhao; Xiao-Li Huang; Phalguni Gupta; Luann Borowski; Zheng Fan; Simon C Watkins; Elaine K Thomas; Charles R Rinaldo
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS.

Authors:  Stefan Kostense; Kristin Vandenberghe; Jeanine Joling; Debbie Van Baarle; Nening Nanlohy; Erik Manting; Frank Miedema
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

8.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

9.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.

Authors:  F Sallusto; M Cella; C Danieli; A Lanzavecchia
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  25 in total

1.  Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

Authors:  L Buonaguro; M L Tornesello; M Tagliamonte; R C Gallo; L X Wang; R Kamin-Lewis; S Abdelwahab; G K Lewis; F M Buonaguro
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

Authors:  Sheng Zhang; Rafael Cubas; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Immunol       Date:  2009-04-18       Impact factor: 4.407

3.  Designing the optimal vaccine: the importance of cytokines and dendritic cells.

Authors:  Penelope A Morel; Michael S Turner
Journal:  Open Vaccine J       Date:  2010

4.  The cellular factors Vps18 and Mon2 are required for efficient production of infectious HIV-1 particles.

Authors:  Yuriko Tomita; Takeshi Noda; Ken Fujii; Tokiko Watanabe; Yuko Morikawa; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

5.  Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation.

Authors:  Patrick Lacasse; Jérôme Denis; Réjean Lapointe; Denis Leclerc; Alain Lamarre
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

6.  Use of the piggyBac transposon to create HIV-1 gag transgenic insect cell lines for continuous VLP production.

Authors:  Alisson G Lynch; Fiona Tanzer; Malcolm J Fraser; Enid G Shephard; Anna-Lise Williamson; Edward P Rybicki
Journal:  BMC Biotechnol       Date:  2010-03-31       Impact factor: 2.563

7.  Nef modulates the immunogenicity of Gag encoded in a non-infectious HIV DNA vaccine.

Authors:  Geraldine Arrode; Ramakrishna Hegde; Yuhuai Jin; Dinesh Kumar Singh; Opendra Narayan; Yahia Chebloune
Journal:  Vaccine       Date:  2008-06-17       Impact factor: 3.641

Review 8.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

9.  Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Authors:  Ellen R Van Gulck; Guido Vanham; Leo Heyndrickx; Sandra Coppens; Katleen Vereecken; Derek Atkinson; Eric Florence; Ilse Kint; Zwi Nisan Berneman; Viggo Van Tendeloo
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

10.  Interaction of Cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivo.

Authors:  Maria J Gonzalez; Emily M Plummer; Chris S Rae; Marianne Manchester
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.